HONG KONG SAR – EQS Newswire – 21 May 2025 – Uni-Bio Science Group Limited (the “Company”, together with its subsidiaries, the “Group”) proudly announces that its new ophthalmology product, \u91d1\u56e0\u5eb7\u00ae<\/sup> (Diquafosol Sodium Eye Drops), has received marketing approval from the China National Medical Products Administration (NMPA) [Approval Number: \u570b\u85e5\u51c6\u5b57H20254149]. This milestone strengthens the Group’s portfolio in ophthalmology, addressing the growing demand for innovative treatments in China’s dry eye syndrome market, which affects an estimated 360 million individuals.<\/p>\n As the Group’s second ophthalmology drug following GeneSoft\u00ae<\/sup>, \u91d1\u56e0\u5eb7\u00ae<\/sup> addresses the underlying causes of dry eye syndrome by activating P2Y2 receptors to stimulate tear fluid and mucin secretion. It offers:\n<\/p>\n China’s dry eye syndrome market is projected to surpass RMB 42 billion by 2030, growing at a CAGR of 28.4%, driven by increased screen time and evolving lifestyles. \u91d1\u56e0\u5eb7\u00ae<\/sup> is well-positioned to capture this growing demand with its proven efficacy and safety, widely recognized since the originator launched in Japan in 2010.<\/p>\n To ensure rapid market penetration, the Group has expanded its sales force and integrated resources across hospitals, pharmacies, and e-commerce platforms. Strategic partnerships with API suppliers have secured high-quality raw materials at competitive costs, further enhancing \u91d1\u56e0\u5eb7\u00ae<\/sup>‘s affordability and market competitiveness.\n<\/p>\n Looking ahead, Uni-Bio Science Group will continue to focus on clinical needs and invest in R&D to expand its ophthalmic drug pipeline. With over 20 years of technological expertise, the Group is committed to delivering high-quality medical solutions, raising the standards of ophthalmic care, and solidifying its leadership in China’s growing ophthalmology market.\n<\/p>\n Hashtag: <\/b>#Uni-BioScience<\/p>\n\n